Nuvation Bio Inc (NYSE:NUVB) shares traded 20.38% higher at $1.16 on Wall Street last session.
In accordance with the data, 6 analysts cover Nuvation Bio Inc (NYSE:NUVB). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $5.00 and a low of $1.80, we find $4.75. Given the previous closing price of $0.96, this indicates a potential upside of 394.79 percent. NUVB stock price is now -14.24% away from the 50-day moving average and -32.22% away from the 200-day moving average. The market capitalization of the company currently stands at $255.13M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
It has been rated a hold by 2 analysts and a buy by 4. Brokers who have rated the stock have averaged $4.08 as their price target over the next twelve months.
With the price target reduced from $5 to $2, Jefferies Downgraded its rating from Buy to Hold for Nuvation Bio Inc (NYSE: NUVB).
In other news, NODELMAN OLEG, Director bought 53,000 shares of the company’s stock on Feb 21. The stock was bought for $72,138 at an average price of $1.36. Upon completion of the transaction, the Director now directly owns 12,674,775 shares in the company, valued at $14.7 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 20, Director NODELMAN OLEG bought 117,100 shares of the business’s stock. A total of $159,490 was incurred on buying the stock at an average price of $1.36. This leaves the insider owning 12,621,775 shares of the company worth $14.64 million. A total of 37.31% of the company’s stock is owned by insiders.
Nuvation Bio Inc (NYSE: NUVB) opened at $0.9900 on Wednesday. During the past 12 months, Nuvation Bio Inc has had a low of $0.95 and a high of $2.55. As of last week, the company has a debt-to-equity ratio of 0.01, a current ratio of 47.51, and a quick ratio of 47.51. The fifty day moving average price for NUVB is $1.3527 and a two-hundred day moving average price translates $1.7113 for the stock.
The latest earnings results from Nuvation Bio Inc (NYSE: NUVB) was released for Jun, 2023.
Nuvation Bio Inc(NUVB) Company Profile
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company’s lead product candidate is NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.
